Vasomotor Symptoms Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Vasomotor Symptoms Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Report Format: PDF+Excel | Report ID: SR112025A6552

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Vasomotor Symptoms - Introduction

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (​2019-2024​) and Forecast (​2025-2035​)
4.4 Market Overview (​2019-2024​) and Forecast (​2025-2035​)
4.5 Competitive Intelligence

5 Vasomotor Symptoms - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Vasomotor Symptoms - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (​2019-2024​)
7.2.2 Epidemiology Forecast (​2025-2035​)
7.2.3 Epidemiology by Age (​2019-2035​)
7.2.4 Epidemiology by Gender (​2019-2035​)
7.2.5 Epidemiology by Type (​2019-2035​)
7.2.6 Diagnosed Cases (​2019-2035​)
7.2.7 Patient Pool/Treated Cases (​2019-2035​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (​2019-2024​)
7.3.2 Epidemiology Forecast (​2025-2035​)
7.3.3 Epidemiology by Age (​2019-2035​)
7.3.4 Epidemiology by Gender (​2019-2035​)
7.3.5 Epidemiology by Type (​2019-2035​)
7.3.6 Diagnosed Cases (​2019-2035​)
7.3.7 Patient Pool/Treated Cases (​2019-2035​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (​2019-2024​)
7.4.2 Epidemiology Forecast (​2025-2035​)
7.4.3 Epidemiology by Age (​2019-2035​)
7.4.4 Epidemiology by Gender (​2019-2035​)
7.4.5 Epidemiology by Type (​2019-2035​)
7.4.6 Diagnosed Cases (​2019-2035​)
7.4.7 Patient Pool/Treated Cases (​2019-2035​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (​2019-2024​)
7.5.2 Epidemiology Forecast (​2025-2035​)
7.5.3 Epidemiology by Age (​2019-2035​)
7.5.4 Epidemiology by Gender (​2019-2035​)
7.5.5 Epidemiology by Type (​2019-2035​)
7.5.6 Diagnosed Cases (​2019-2035​)
7.5.7 Patient Pool/Treated Cases (​2019-2035​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (​2019-2024​)
7.6.2 Epidemiology Forecast (​2025-2035​)
7.6.3 Epidemiology by Age (​2019-2035​)
7.6.4 Epidemiology by Gender (​2019-2035​)
7.6.5 Epidemiology by Type (​2019-2035​)
7.6.6 Diagnosed Cases (​2019-2035​)
7.6.7 Patient Pool/Treated Cases (​2019-2035​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (​2019-2024​)
7.7.2 Epidemiology Forecast (​2025-2035​)
7.7.3 Epidemiology by Age (​2019-2035​)
7.7.4 Epidemiology by Gender (​2019-2035​)
7.7.5 Epidemiology by Type (​2019-2035​)
7.7.6 Diagnosed Cases (​2019-2035​)
7.7.7 Patient Pool/Treated Cases (​2019-2035​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (​2019-2024​)
7.8.2 Epidemiology Forecast (​2025-2035​)
7.8.3 Epidemiology by Age (​2019-2035​)
7.8.4 Epidemiology by Gender (​2019-2035​)
7.8.5 Epidemiology by Type (​2019-2035​)
7.8.6 Diagnosed Cases (​2019-2035​)
7.8.7 Patient Pool/Treated Cases (​2019-2035​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (​2019-2024​)
7.9.2 Epidemiology Forecast (​2025-2035​)
7.9.3 Epidemiology by Age (​2019-2035​)
7.9.4 Epidemiology by Gender (​2019-2035​)
7.9.5 Epidemiology by Type (​2019-2035​)
7.9.6 Diagnosed Cases (​2019-2035​)
7.9.7 Patient Pool/Treated Cases (​2019-2035​)

8 Vasomotor Symptoms - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Vasomotor Symptoms - Unmet Needs

10 Vasomotor Symptoms - Key Endpoints of Treatment

11 Vasomotor Symptoms - Marketed Products
11.1 List of Vasomotor Symptoms Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name

11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Vasomotor Symptoms - Pipeline Drugs
12.1 List of Vasomotor Symptoms Pipeline Drugs Across the Top 7 Markets
12.1.1 Asimadoline (TP0052) - Tioga Pharmaceuticals

12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13 Vasomotor Symptoms - Attribute Analysis of Key Marketed and Pipeline Drugs
 
14 Vasomotor Symptoms – Clinical Trial Landscape

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Vasomotor Symptoms - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets

15.2.1    Vasomotor Symptoms - Market Size
15.2.1.1 Market Size (​2019-2024​)
15.2.1.2 Market Forecast (​2025-2035​)
15.2.2    Vasomotor Symptoms - Market Size by Therapies
15.2.2.1 Market Size by Therapies (​2019-2024​)
15.2.2.2 Market Forecast by Therapies (​2025-2035​)
15.3 Market Scenario - United States
15.3.1    Vasomotor Symptoms - Market Size
15.3.1.1 Market Size (​2019-2024​)
15.3.1.2 Market Forecast (​2025-2035​)
15.3.2    Vasomotor Symptoms - Market Size by Therapies
15.3.2.1 Market Size by Therapies (​2019-2024​)
15.3.2.2 Market Forecast by Therapies (​2025-2035​)
15.3.3    Vasomotor Symptoms - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1    Vasomotor Symptoms - Market Size
15.4.1.1 Market Size (​2019-2024​)
15.4.1.2 Market Forecast (​2025-2035​)
15.4.2    Vasomotor Symptoms - Market Size by Therapies
15.4.2.1 Market Size by Therapies (​2019-2024​)
15.4.2.2 Market Forecast by Therapies (​2025-2035​)
15.4.3    Vasomotor Symptoms - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1    Vasomotor Symptoms - Market Size
15.5.1.1 Market Size (​2019-2024​)
15.5.1.2 Market Forecast (​2025-2035​)
15.5.2    Vasomotor Symptoms - Market Size by Therapies
15.5.2.1 Market Size by Therapies (​2019-2024​)
15.5.2.2 Market Forecast by Therapies (​2025-2035​)
15.5.3    Vasomotor Symptoms - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1    Vasomotor Symptoms - Market Size
15.6.1.1 Market Size (​2019-2024​)
15.6.1.2 Market Forecast (​2025-2035​)
15.6.2    Vasomotor Symptoms - Market Size by Therapies
15.6.2.1 Market Size by Therapies (​2019-2024​)
15.6.2.2 Market Forecast by Therapies (​2025-2035​)
15.6.3    Vasomotor Symptoms - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1    Vasomotor Symptoms - Market Size
15.7.1.1 Market Size (​2019-2024​)
15.7.1.2 Market Forecast (​2025-2035​)
15.7.2    Vasomotor Symptoms - Market Size by Therapies
15.7.2.1 Market Size by Therapies (​2019-2024​)
15.7.2.2 Market Forecast by Therapies (​2025-2035​)
15.7.3    Vasomotor Symptoms - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1    Vasomotor Symptoms - Market Size
15.8.1.1 Market Size (​2019-2024​)
15.8.1.2 Market Forecast (​2025-2035​)
15.8.2    Vasomotor Symptoms - Market Size by Therapies
15.8.2.1 Market Size by Therapies (​2019-2024​)
15.8.2.2 Market Forecast by Therapies (​2025-2035​)
15.8.3    Vasomotor Symptoms - Access and Reimbursement Overview
15.9   Market Scenario - Japan
15.9.1    Vasomotor Symptoms  - Market Size
15.9.1.1 Market Size (​2019-2024​)
15.9.1.2 Market Forecast (​2025-2035​)
15.9.2    Vasomotor Symptoms - Market Size by Therapies
15.9.2.1 Market Size by Therapies (​2019-2024​)
15.9.2.2 Market Forecast by Therapies (​2025-2035​)
15.9.3    Vasomotor Symptoms - Access and Reimbursement Overview

16 Vasomotor Symptoms - Recent Events and Inputs from Key Opinion Leaders

17 Vasomotor Symptoms Market - SWOT Analysis

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats     

18 Vasomotor Symptoms Market – Strategic Recommendations

19 Appendix

Vasomotor Symptoms Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-201-971-6302

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials